Profile data is unavailable for this security.
About the company
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
- Revenue in USD (TTM)63.17bn
- Net income in USD12.15bn
- Incorporated1970
- Employees72.00k
- LocationMerck & Co Inc2000 Galloping Hill RoadKENILWORTH 07033United StatesUSA
- Phone+1 (908) 740-4000
- Fax+1 (908) 423-1987
- Websitehttps://www.merck.com/
Mergers & acquisitions
| Acquired company | MRK:NYQ since announced | Transaction value |
|---|---|---|
| Modifi Biosciences Inc | -5.49% | 1.33bn |
| Unity Semiconductor Sas | -19.94% | -- |
| Eyebiotech Ltd | -20.07% | 3.00bn |
| Abceutics Inc | -21.05% | 208.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | 60.11bn | 4.27bn | 142.41bn | 88.00k | 33.79 | 1.54 | 12.72 | 2.37 | 0.7438 | 0.7399 | 10.57 | 16.29 | 0.2767 | 1.60 | 4.71 | 683,079.60 | 1.98 | 8.20 | 2.39 | 10.40 | 70.82 | 69.34 | 7.16 | 22.68 | 0.729 | -- | 0.4225 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 32.53bn | 4.23bn | 155.83bn | 26.70k | 37.09 | 20.70 | 15.89 | 4.79 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Merck & Co Inc | 63.17bn | 12.15bn | 252.61bn | 72.00k | 20.94 | 5.68 | 15.38 | 4.00 | 4.77 | 4.77 | 24.95 | 17.58 | 0.5634 | 2.39 | 5.80 | 877,416.70 | 10.85 | 7.70 | 14.19 | 10.29 | 76.59 | 72.26 | 19.25 | 15.03 | 1.15 | 24.33 | 0.4611 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 55.53bn | 5.08bn | 303.47bn | 50.00k | 59.91 | 50.31 | 22.46 | 5.46 | 2.87 | 2.87 | 31.32 | 3.41 | 0.3972 | 4.31 | 4.85 | 1,110,660.00 | 3.67 | 6.55 | 5.09 | 8.40 | 67.25 | 69.74 | 9.24 | 16.46 | 0.5419 | 7.88 | 0.9213 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Johnson & Johnson | 87.70bn | 14.77bn | 374.39bn | 131.90k | 25.56 | 5.34 | 16.98 | 4.27 | 6.08 | 6.05 | 36.12 | 29.14 | 0.5094 | 2.27 | 5.66 | 664,867.30 | 8.58 | 8.93 | 11.90 | 11.96 | 69.16 | 68.17 | 16.84 | 18.86 | 0.7853 | -- | 0.3376 | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 237.78m | 9.38% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 133.16m | 5.25% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 119.03m | 4.70% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 72.97m | 2.88% |
| Geode Capital Management LLCas of 30 Sep 2024 | 59.16m | 2.33% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 40.99m | 1.62% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 33.81m | 1.33% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 25.66m | 1.01% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024 | 24.80m | 0.98% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 20.92m | 0.83% |
